United States

People: Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

3:31pm EDT
Change (% chg)

$-1.13 (-5.93%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Perry, Michael 

Dr. Michael S. Perry, Ph.D., is the Lead Independent Director of Arrowhead Pharmaceuticals Inc. Dr. Perry is currently Senior Vice President and Chief Scientific Officer, Global Business Development and Licensing at Novartis Pharma. Prior to his appointment at Novartis, Dr. Perry was a Venture Partner with Bay City Capital LLP from 2005 until November 2012 and President and Chief Medical Officer of Poniard Pharmaceuticals from 2010 to November 2012. Dr. Perry also currently serves as a member of the board of directors of AmpliPhi Biosciences Corporation and Avita Medical. Dr. Perry was Chief Development Officer at VIA Pharmaceuticals, Inc., a publicly held drug development company, from April 2005 until May 2009. Prior thereto, he served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from June 2003 to April 2005. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter BioScience. From 1997 to 2000, Dr. Perry was President and Chief Executive Officer of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp. and from 1994 to 1997, he was Vice President of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals). Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Pharmacology and a B.Sc. in Physics from the University of Guelph, Ontario, Canada. Dr. Perry is a graduate of the International Management Program at Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 67,438
Restricted Stock Awards, USD 124,000
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 191,438

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Douglass Given


Christopher Anzalone


Kenneth Myszkowski


Bruce Given


Patrick O'Brien


Michael Perry

As Of  29 Sep 2017